Roche announced that its oral breast‑cancer candidate failed a crucial Phase 3 first‑line study, dashing expectations that the drug could become a major revenue driver. The company had previously described the pill as a potential blockbuster; the trial miss now forces re‑evaluation of the program’s development plan and commercial forecasts. The result will influence Roche’s oncology portfolio prioritization and competitive positioning in hormone‑refractory breast cancer.